|
市場調查報告書
未來的基因資料庫：藥物研發規範、倫理、投資、傳遞
The Future of Biobanks: Regulation, ethics, investment and the humanization of drug discovery
|
未來的基因資料庫：藥物研發規範、倫理、投資、傳遞 是由出版商Business Insights在2009年03月所出版的。
這份英文市場調查報告書包含129 pages 價格從美金3835起跳。
本報告書內容包括：基因資料庫業界主要動向、改善基礎建設的動向、基因資料庫應用、美國180家基因資料庫動向、相關法律與倫理問題等，內容綱要摘記如下：
摘要
第1章 概要
- 總括
- 前言
- 基因資料庫定義
- 歷史概要
- 基因資料庫的科學與商業適切性
- 標的治療藥物
- 診斷與愈後診斷實驗
- 新藥物研發
- 疾病流行病學
- 未來觀察
第2章 基因資料庫動向
- 前言
- 基因資料庫的極限
- 改善基因資料庫的作法
- 樣本變動性
- 樣本品質
- 以前的基因資料庫
- 最近的基因資料庫
- 基因資料庫成本
- 傳遞
- 未來觀察
第3章 以個體數為本的基因資料庫
- 前言
- 個體數基因資料庫種類
- 個體群研究
- 設立者
- 國立基因資料庫
- 未來觀察
第4章 以疾病為本的基因資料庫
- 前言
- 疾病基因資料庫的成長
- 健康樣本基因資料庫
- 合作網
- 未來觀察
第5章 民間基因資料庫
- 前言
- 英國認可的基因資料庫
- 委託服務供應商
- 生物標的藥物研發企業
- 藥物收集
- 研究合作
- 治療實驗
- 未來觀察
第6章 規範與倫理問題
- 總括
- 前言
- 目前規範框架
- 告知同意
- 取消與擁有
- 保密
- 商業化
- 未來觀察
附錄
圖表
Abstract
Biobanks collect and store human biospecimens, playing a vital role in the
development of novel drugs and diagnostics. In recent years, large
population-based biobanks have been established which monitor the health
status of participants over time to assess the natural occurrence and
progression of common diseases. Hundreds of disease-based biobanks are located
around the world, which are a valuable resource for biomarker discovery as
well as for studying progression, mortality and responses to treatment. - The
Future of Biobanks - is a new report published by Business Insights that
examines major trends in the biobanking industry and identifies the key
initiatives to upgrade the biobanking infrastructure. This report explores the
applications of biobanks and provides examples of how large sets of
high-quality biosamples are creating new ways to diagnose, prevent and treat
diseases. The activities of over 180 US biobanks are assessed to illustrate
how the scale and scope of biobanking is changing. This report also evaluates
the limitations of biobanks, in addition to reviewing the unique legal,
regulatory and ethical issues that surround this new frontier of biomolecular
research.
Table of Contents
The Future of Biobanks Executive summary Overview Biobanking trends
Population-based biobanks Disease-based biobanks Private-sector biobanks
Regulatory and ethical issues
Chapter 1 Overview
- Summary
- Introduction
- Definition of biobanks
- Historical context
- Scientific and commercial relevance of biobanks
- Targeted therapeutics
- Diagnostic and prognostic tests
- Drug development
- Disease etiology
- Future outlook
Chapter 2 Trends in biobanking
- Introduction
- Introduction
- The limitations of biobanks
- Initiatives to improve biobanks
- Sample variability
- Sample quality
- Older biobanks
- Modern biobanks
- Biobanking costs
- Increasing harmonization
- Future outlook
Chapter 3 Population-based biobanks
- Introduction
- Introduction
- Types of population biobanks
- Cohort studies
- Founder population biobanks
- deCODE Genetics
- CARTaGENE
- Genizon Biosciences
- Jurilab
- National population biobanks
- UK Biobank
- LifeGene
- Estonian biobank
- Latvian biobank
- Canadian Partnership for Tomorrow Project
- Other national biobanks
- Future outlook
Chapter 4 Disease-based biobanks
- Introduction
- Introduction
- Growth in disease-based biobanks
- Cancer biobanks
- Other diseases
- Healthy sample biobanks
- Collaborative networks
- onCORE UK
- International Genomics Consortium
- Cancer Genome Atlas
- Future outlook
Chapter 5 Private-sector biobanks
- Introduction
- Introduction
- Licensed biobanks in the UK
- Contract service providers
- Biomarker discovery companies
- Pharmaceutical collections
- Research collaborations
- Clinical trials
- Future outlook
Chapter 6 Regulatory and ethical issues
- Summary
- Introduction
- Current regulatory framework
- Informed consent
- Withdrawal and ownership
- Confidentiality
- Commercialization
- Future outlook
Appendix
List of Figures
- Figure 1.1: Cumulative number of DNA samples banked in population-based
studies*, 1970-2009
- Figure 1.2: NIH sponsored clinical trials conducting gene expression
profiling, 2000-08
- Figure 2.1: Geographical distribution of biobanks
- Figure 2.2: Drivers and resistors
- Figure 2.3: The evolution of biobanks
- Figure 4.1: Number of diseases-based biobanks, by therapy area, US
1995-2008
- Figure 5.1: Establishments licensed to operate biobanks, by sector,
England, Wales and Northern Ireland, 2008
- Figure 5.2: Examples of private-sector biobanks
List of Tables
- Table 1.1: Applications of biobanks
- Table 2.1: Types of biobanks
- Table 3.1: Selected population-based cohort studies
- Table 3.2: Population-based biobanks
- Table 4.1: Selected cancer biobanks, US
|
